Oncode Oncology Bridge Fund

Oncode Oncology Bridge Fund operates as an early-stage venture capital fund dedicated to advancing innovative cancer research from academic settings to clinical application. It provides crucial seed financing and investment to emerging companies focused on developing next-generation solutions for oncology. The fund's primary activity involves identifying and supporting startups that aim to translate scientific breakthroughs into tangible new treatment options and diagnostic methods for cancer.

Established in 2018 in Utrecht, Netherlands, the Oncode Oncology Bridge Fund was formed with the insight that early-stage oncology research requires specialized capital and support to bridge the gap between discovery and commercial development. It emerged from the Oncode Institute's broader mission to accelerate cancer innovation, later scaling its investment model with partners like Ligase BioPartners for subsequent funds. This foundation enables the direct channeling of resources into promising academic spin-offs.

The fund's primary beneficiaries are early-stage oncology start-up companies that receive initial investment to develop novel therapies and diagnostics. Ultimately, the vision is to significantly improve treatment outcomes for cancer patients globally by facilitating the rapid and effective development of advanced medical solutions. Through strategic capital deployment, the fund aims to accelerate the availability of new and impactful cancer treatments.